Key result
Bucindolol increased cAMP levels in human myocardium by a maximum of 1.64-fold over control (P<0.01), exhibiting approximately 60% of the beta-adrenergic agonist activity of xamoterol.
Why the study?
Does bucindolol increase cAMP accumulation in human myocardium?
Population
Myocardial strips (approximately 1 mm³) obtained from rat and nonfailing human hearts
Comparison
Bucindolol vs Control and other beta-adrenergic agents
Design
Preclinical
Follow-up
15 minutes
Authors
Loading...
May explain bucindolol's neutral HF mortality effect; leaves open confirmation in failing myocardium.
Does bucindolol increase cAMP accumulation in human myocardium?
Effect estimate: 1.64-fold increase
p-value: p=<0.01
Bucindolol exhibits partial beta-adrenergic agonist activity in normal human myocardial tissue, potentially explaining its failure to reduce mortality in heart failure trials.
Andréka et al. (2002) studied Normal human myocardial tissue. Bucindolol vs. Control, carvedilol, propranolol, metoprolol, xamoterol was evaluated on cAMP accumulation (1.64-fold increase, p=<0.01). Bucindolol increased cAMP levels in human myocardium by a maximum of 1.64-fold over control (P<0.01), exhibiting approximately 60% of the beta-adrenergic agonist activity of xamoterol.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: